ADiTx Therapeutics, Inc. Contracts & Agreements

Amendment No. 4 to Amended and Restated Merger Agreement (Filed With SEC on November 19, 2024)

Form of Securities Purchase Agreement (Oct 28, 2024) (Filed With SEC on October 30, 2024)

Form of Registration Rights Agreement (Oct 28, 2024) (Filed With SEC on October 30, 2024)

Amendment No. 3 to Amended and Restated Merger Agreement (Filed With SEC on October 3, 2024)

Form of Securities Purchase Agreement (Oct 2024) (Filed With SEC on October 3, 2024)

Form of Registration Rights Agreement (Oct 2024) (Filed With SEC on October 3, 2024)

Form of Senior Note (September 2024) (Filed With SEC on September 23, 2024)

Form of Securities Purchase Agreement (Sept 2024) (Filed With SEC on September 23, 2024)

Form of Registration Rights Agreement (Sept 2024) (Filed With SEC on September 23, 2024)

Market Development and Collaboration Agreement (Filed With SEC on September 23, 2024)

Amendment No. 2 to Amended and Restated Agreement and Plan of Merger dated as of September 6, 2024, by and among Aditxt, Inc., Adifem, Inc. and Evofem Biosciences, Inc (Filed With SEC on September 6, 2024)

Form of Waiver to Senior Note (Filed With SEC on August 28, 2024)

Form of Letter Agreement (Filed With SEC on August 28, 2024)

Third Amending Agreement between Appili Therapeutics, Inc., Aditxt, Inc. and Adivir, Inc. dated as of August 20, 2024 (Filed With SEC on August 21, 2024)

Amendment No. 1 to Amended and Restated Merger Agreement (Filed With SEC on August 19, 2024)

Form of Securities Purchase Agreement (Filed With SEC on August 13, 2024)

Form of Registration Rights Agreement (Filed With SEC on August 13, 2024)

Form of Pre-Funded Warrant (Filed With SEC on August 9, 2024)

Form of Placement Agent Warrant (Filed With SEC on August 9, 2024)

Form of Securities Purchase Agreement (Filed With SEC on August 9, 2024)

Form of Lock-Up Agreement (Filed With SEC on August 9, 2024)

Form of Warrant (Filed With SEC on August 8, 2024)

Exchange Agreement dated August 7, 2024 (Filed With SEC on August 8, 2024)

Second Amending Agreement between Appili Therapeutics, Inc., Aditxt, Inc. and Adivir, Inc. dated as of July 18, 2024 (Filed With SEC on July 22, 2024)

Amended and Restated Agreement and Plan of Merger among Aditxt, Inc., Adifem, Inc. f/k/a Adicure, Inc. and Evofem Biosciences, Inc. dated as of July 12, 2024 (Filed With SEC on July 18, 2024)

Form of Warrant (Filed With SEC on July 18, 2024)

Waiver Agreement by and between Evofem Biosciences, Inc., Aditxt, Inc. and Adifem, Inc. dated July 12, 2024 (Filed With SEC on July 18, 2024)

Form of Securities Purchase Agreement (Filed With SEC on July 18, 2024)

Form of Senior Note (Filed With SEC on July 18, 2024)

Securities Purchase Agreement by and among Evofem Biosciences, Inc. and Aditxt, Inc. dated July 12, 2024 (Filed With SEC on July 18, 2024)

Registration Rights Agreement by and among Evofem Biosciences, Inc. and Aditxt, Inc. dated July 12, 2024 (Filed With SEC on July 18, 2024)

Form of Warrant (July 2024) (Filed With SEC on July 9, 2024)

Form of Securities Purchase Agreement (July 2024) (Filed With SEC on July 9, 2024)

Form of Senior Note (July 2024) (Filed With SEC on July 9, 2024)

Form of Amendment to Common Stock Purchase Warrants (July 2024) (Filed With SEC on July 9, 2024)

Amending Agreement between Appili Therapeutics, Inc., Aditxt, Inc. and Adivir, Inc. dated as of July 1, 2024 (Filed With SEC on July 8, 2024)

Unsecured Promissory Note dated June 20, 2024 (Filed With SEC on June 25, 2024)

Form of Warrant (Filed With SEC on June 5, 2024)

Form of Securities Purchase Agreement (Filed With SEC on May 28, 2024)

Form of Senior Note (May 2024) (Filed With SEC on May 28, 2024)

Form of Senior Note (Filed With SEC on May 22, 2024)

Unsecured Promissory Note dated May 9, 2024 (Filed With SEC on May 13, 2024)

Form of Securities Purchase Agreement dated as of May 2, 2024 (Filed With SEC on May 8, 2024)

Form of Registration Rights Agreement dated as of May 2, 2024 (Filed With SEC on May 8, 2024)

Common Stock Purchase Agreement dated as of May 2, 2024 by and among Aditxt, Inc. and the Investor (Filed With SEC on May 7, 2024)

Registration Rights Agreement dated as of May 2, 2024 by and between the Investor and Aditxt, Inc (Filed With SEC on May 7, 2024)

Reinstatement and Fourth Amendment to the Merger Agreement dated May 2, 2024 (Filed With SEC on May 3, 2024)

Unsecured Promissory Note dated April 10, 2024 (Filed With SEC on April 12, 2024)

Arrangement Agreement between Appili Therapeutics, Inc., Aditxt, Inc. and Adivir, Inc. dated as of April 1, 2024 (Filed With SEC on April 4, 2024)

Unsecured Promissory Note dated March 7, 2024 (Filed With SEC on March 11, 2024)

Third Amendment to Agreement and Plan of Merger dated as of February 29, 2024, by and among Aditxt, Inc., Adicure, Inc. and Evofem Biosciences, Inc (Filed With SEC on March 4, 2024)

Form of Unsecured Promissory Note (Filed With SEC on March 1, 2024)

Assignment Agreement dated as of February 26, 2024 (Filed With SEC on February 29, 2024)

Form of Amendment No. 4 to January 2024 Secured Notes (Filed With SEC on February 29, 2024)

Payoff Letter dated February 26, 2024 (Filed With SEC on February 29, 2024)

Engagement Letter dated February 16, 2024 (Filed With SEC on February 21, 2024)

Unsecured Promissory Note dated February 15, 2024 (Filed With SEC on February 16, 2024)

Form of Unsecured Promissory Note dated February 7, 2024 (Filed With SEC on February 9, 2024)

Form of Amendment No. 3 to January 2024 Secured Notes (Filed With SEC on February 6, 2024)

Form of Amendment No. 2 to September 2024 Secured Notes (Filed With SEC on February 6, 2024)

Second Amendment to Agreement and Plan of Merger dated as of January 8, 2024, by and among Aditxt, Inc., Adicure, Inc. and Evofem Biosciences, Inc (Filed With SEC on February 2, 2024)

Form of Business Loan and Security Agreement dated January 24, 2024 (Filed With SEC on January 30, 2024)

Assignment Agreement dated January 24, 2024 (Filed With SEC on January 30, 2024)

Form of Securities Purchase Agreement dated January 24, 2024 (Filed With SEC on January 30, 2024)

Patent Assignment dated January 24, 2024 (Filed With SEC on January 30, 2024)

Form of Voting Agreement (Filed With SEC on January 30, 2024)

Form of Company Warrant (Filed With SEC on January 9, 2024)

First Amendment to Asset Purchase Agreement dated January 4, 2024 by and among Aditxt, Inc., Pearsanta, Inc., and MDNA Life Sciences, Inc (Filed With SEC on January 9, 2024)

First Amendment to Agreement and Plan of Merger dated as of January 8, 2024, by and among Aditxt, Inc., Adicure, Inc. and Evofem Biosciences, Inc (Filed With SEC on January 9, 2024)

Form of Pre-Funded Warrant (Filed With SEC on January 5, 2024)

Form of Common Warrant (Filed With SEC on January 5, 2024)

Form of Placement Agent Warrant (Filed With SEC on January 5, 2024)

Form of Securities Purchase Agreement (Filed With SEC on January 5, 2024)

Form of Registration Rights Agreement (Filed With SEC on January 5, 2024)

Form of Amendment No. 1 to January 2024 Secured Notes (Filed With SEC on January 5, 2024)

Form of Amendment No. 2 to January 2024 Secured Notes (Filed With SEC on January 5, 2024)

Form of Amendment No. 1 to September 2024 Secured Notes (Filed With SEC on January 5, 2024)

Exchange Agreement, dated December 28, 2023 by and between the Company and the holders signatory thereto (Filed With SEC on January 2, 2024)

Form of Voting Agreement (Filed With SEC on January 2, 2024)

Exchange Agreement, dated December 22, 2023 by and between the Company and the holders signatory thereto (Filed With SEC on December 26, 2023)

Registration Rights Agreement, dated December 22, 2023 by and between the Company and the holders signatory thereto (Filed With SEC on December 26, 2023)

Form of Consulting Agreement (Filed With SEC on December 22, 2023)

Form of Unsecured Promissory Note dated December 20, 2023 (Filed With SEC on December 22, 2023)

Asset Purchase Agreement by and among Aditxt, Inc., Pearsanta, Inc. and MDNA Life Sciences, Inc. dated as of December 17, 2023 (Filed With SEC on December 21, 2023)

Agreement and Plan of Merger among Aditxt, Inc., Adicure, Inc. and Evofem Biosciences, Inc. dated as of December 11, 2023 (Filed With SEC on December 12, 2023)

Assignment Agreement dated as of December 11, 2023 (Filed With SEC on December 12, 2023)

Form of December 2023 Secured Note (Filed With SEC on December 12, 2023)

Form of September 2024 Secured Note (Filed With SEC on December 12, 2023)

Form of Royalty Note (Filed With SEC on December 12, 2023)

IP Security Agreement dated December 11, 2023 (Filed With SEC on December 12, 2023)

Security Agreement dated December 11, 2023 (Filed With SEC on December 12, 2023)

Form of Unsecured Promissory Note (Filed With SEC on December 8, 2023)

Form of Unsecured Promissory Note (Filed With SEC on December 1, 2023)

Form of Business Loan and Security Agreement dated November 7, 2023 (Filed With SEC on November 9, 2023)

Form of Agreement for the Purchase and Sale of Future Receipts (Filed With SEC on October 11, 2023)

Second Amendment to Separation Agreement and General Release dated September 18, 2023 (Filed With SEC on September 21, 2023)

Form of Pre-Funded Warrant (Filed With SEC on September 6, 2023)

Form of Warrant (Filed With SEC on September 6, 2023)

Form of Placement Agent Warrant (Filed With SEC on September 6, 2023)

Form of Securities Purchase Agreement (Filed With SEC on September 6, 2023)

Form of Registration Rights Agreement (Filed With SEC on September 6, 2023)

Form of Business Loan and Security Agreement dated August 23, 2023 (Filed With SEC on August 28, 2023)

Amendment to Separation Agreement and General Release dated August 15, 2023 (Filed With SEC on August 21, 2023)

Form of Securities Purchase Agreement (Filed With SEC on July 28, 2023)

Form of Note (Filed With SEC on July 28, 2023)

Form of Security Agreement (Filed With SEC on July 28, 2023)

Form of Registration Rights Agreement (Filed With SEC on July 28, 2023)

Separation Agreement and General Release by and between Matthew Shatzkes and Aditxt, Inc (Filed With SEC on July 27, 2023)

Subscription and Investment Representation Agreement, dated July 11, 2023, by and between Aditxt, Inc., and the purchaser signatory thereto (Filed With SEC on July 14, 2023)

Form of Securities Purchase Agreement (Filed With SEC on July 7, 2023)

Form of Note (Filed With SEC on July 7, 2023)

Form of Security Agreement (Filed With SEC on July 7, 2023)

Form of Registration Rights Agreement (Filed With SEC on July 7, 2023)

Form of Business Loan and Security Agreement dated July 3, 2023 (Filed With SEC on July 7, 2023)

Form of Unsecured Promissory Note (Filed With SEC on June 16, 2023)

Form of Agreement for the Purchase and Sale of Future Receipts (Filed With SEC on May 31, 2023)

Unsecured Promissory Note dated May 25, 2023 (Filed With SEC on May 31, 2023)

Asset Purchase Agreement dated as of April 19, 2023 by and between the Company and Cellvera, Ltd., et al (Filed With SEC on April 25, 2023)

Form of Unsecured Promissory Note (Filed With SEC on April 25, 2023)

Form of Business Loan and Security Agreement, dated April 24, 2023 (Filed With SEC on April 25, 2023)

Form of Pre-Funded Warrant (Filed With SEC on April 24, 2023)

Form of Warrant (Filed With SEC on April 24, 2023)

Form of Placement Agent Warrant (Filed With SEC on April 24, 2023)

Form of Securities Purchase Agreement (Filed With SEC on April 24, 2023)

Form of Business Loan and Security Agreement dated April 4, 2023 (Filed With SEC on April 7, 2023)

Form of Consulting Agreement (Filed With SEC on March 21, 2023)

Amendment No. 2 to Series C Warrant Agent Agreement (Filed With SEC on December 23, 2022)

Form of Amended and Restated Unit Purchase Option (Filed With SEC on December 23, 2022)

At The Market Offering Agreement dated December 20, 2022 between Aditxt, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on December 20, 2022)

Form of Securities Purchase Agreement (Filed With SEC on September 15, 2022)

Form of Warrant (Filed With SEC on September 15, 2022)

Form of Placement Agents Warrant (Filed With SEC on September 15, 2022)

Form of Pre-Funded Warrant (Filed With SEC on September 15, 2022)

Form of August 2022 Note (Filed With SEC on September 14, 2022)

Form of August 2022 Warrant (Filed With SEC on September 14, 2022)

Form of First Amendment and Waiver effective as of August 31, 2022 (Filed With SEC on September 7, 2022)

Form of Warrant (Filed With SEC on September 7, 2022)

Form of Securities Purchase Agreement (Filed With SEC on August 10, 2022)

Form of August 2022 Note (Filed With SEC on August 10, 2022)

Form of August 2022 Warrant (Filed With SEC on August 10, 2022)

Form of Registration Rights Agreement (Filed With SEC on August 10, 2022)

Form of Security Agreement (Filed With SEC on August 10, 2022)

Unsecured Promissory Note dated July 21, 2022 (Filed With SEC on July 26, 2022)

Subscription and Investment Representation Agreement, dated July 19, 2022, by and between Aditxt, Inc.. and the purchaser signatory thereto (Filed With SEC on July 20, 2022)

Second Amendment to Share Exchange Agreement by and between AiPharma Group Ltd. and Aditxt, Inc. dated June 10, 2022 (Filed With SEC on June 16, 2022)

Amendment No. 1 to Series C Warrant Agent Agreement dated June 15, 2022 (Filed With SEC on June 15, 2022)

Inducement Offer to Exercise Series C Common Stock Purchase Warrants (Filed With SEC on June 15, 2022)

Form of New Warrant (Filed With SEC on June 15, 2022)

Form of Placement Agent Warrant (Filed With SEC on June 15, 2022)

Form of Agreement for the Purchase and Sale of Future Receipts (Filed With SEC on June 3, 2022)

Forbearance Agreement and Eight Amendment to Secured Credit Agreement dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Security Agreement between Cellvera Holdings and Aditxt, Inc. dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Security Agreement between Cellvera Development LLC and Aditxt, Inc. dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Security Agreement between Cellvera Global Holdings LLC and Aditxt, Inc. dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Amended and Restated Security Agreement between Cellvera Asia Limited and Aditxt, Inc. dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Revenue Sharing Agreement by and among Aditxt, Inc., Cellvera Global Holdings LLC and Cellvera Asia Limited dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Amendment to Share Exchange Agreement by and between AiPharma Group Ltd. and Aditxt, Inc. dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

Second Amendment to Secured Credit Agreement with AiPharma Global Holdings LLC dated October 27, 2021 (Filed With SEC on March 31, 2022)

Form of Warrant Reduction and Release Agreement dated as of November 24, 2021 (Filed With SEC on March 31, 2022)

First Amendment to Transaction Agreement dated November 30, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Third Amendment to Secured Credit Agreement dated November 30, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (Filed With SEC on March 31, 2022)

Second Amendment to Transaction Agreement dated December 7, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Secured Credit Agreement, dated as of December 8, 2021, by and among the Company and the Target Company (Filed With SEC on March 31, 2022)

Third Amendment to Transaction Agreement dated December 17, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Fifth Amendment to Secured Credit Agreement dated December 22, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (Filed With SEC on March 31, 2022)

Sixth Amendment to Secured Credit Agreement dated December 28, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (Filed With SEC on March 31, 2022)

Employment Agreement between Aditxt, Inc. and Matthew Shatzkes, Chief Legal Officer and General Counsel (Filed With SEC on March 31, 2022)

Forbearance Agreement and Seventh Amendment to Secured Credit Agreement dated as of February 14, 2022 by and among the Company, Cellvera Global Holdings LLC, Cellvera Holdings... (Filed With SEC on March 31, 2022)

Fourth Amendment to Transaction Agreement dated December 22,2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Share Exchange Agreement dated as of December 28, 2021 by and between AiPharma Group Ltd. and Aditxt, Inc (Filed With SEC on December 28, 2021)

Underwriting Agreement between the Company and Dawson James Securities, Inc., dated December 1, 2021 (Filed With SEC on December 7, 2021)

Secured Credit Agreement, dated as of August 27, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (Filed With SEC on November 15, 2021)

Security Agreement, dated as of August 27, 2021 by and between AiPharma Asia Limited and the Company (Filed With SEC on November 15, 2021)

Security Agreement, dated as of August 27, 2021 by and between AiPharma Limited and the Company (Filed With SEC on November 15, 2021)

Security Agreement AiPharma Limited and Aditxt (BVI Law) (Filed With SEC on November 15, 2021)

Floating Charge (Filed With SEC on November 15, 2021)

Transaction Agreement, dated as of October 4, 2021 by and between the company and AiPharma Global Holdings LLC (Filed With SEC on November 15, 2021)

First Amendment to Secured Credit Agreement with AiPharma Global Holding LLC (Filed With SEC on November 15, 2021)

Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Amro Albanna, Chief Executive Officer (Filed With SEC on November 15, 2021)

Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Corinne Pankovcin, President and Secretary (Filed With SEC on November 15, 2021)

Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Thomas Farley, Chief Financial Officer (Filed With SEC on November 15, 2021)

Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Shahrokh Shabahang, Chief Innovation Officer (Filed With SEC on November 15, 2021)

Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Rowena Albanna, Chief Operating Officer (Filed With SEC on November 15, 2021)

Underwriting Agreement between the Company and Revere Securities LLC dated October 18, 2021 (Filed With SEC on October 20, 2021)

Form of Warrant (Filed With SEC on August 30, 2021)

Form of Securities Purchase Agreement (Filed With SEC on August 30, 2021)

Placement Agency Agreement (Filed With SEC on August 30, 2021)

Form of Placement Agent Warrant (Filed With SEC on August 30, 2021)

Waiver and Defeasance Agreement (Filed With SEC on August 30, 2021)

Lease Agreement, dated as of May 4, 2021, by and between LS Biotech Eight, LLC, as Landlord, and Aditx Therapeutics, Inc., as Tenant (Filed With SEC on May 10, 2021)

Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 25, 2021)

Employment Agreement, dated February 24, 2021 (Filed With SEC on February 26, 2021)

2021 Omnibus Equity Incentive Plan (Filed With SEC on February 26, 2021)

Form of Senior Secured Convertible Promissory Note (Filed With SEC on January 26, 2021)

Form of Warrant (Filed With SEC on January 26, 2021)

Form of Securities Purchase Agreement (Filed With SEC on January 26, 2021)

Form of Registration Rights Agreement (Filed With SEC on January 26, 2021)

Form of Placement Agent Warrant (Filed With SEC on January 26, 2021)

Consulting Agreement, dated November 18, 2020 (Filed With SEC on November 23, 2020)

Underwriting Agreement, dated September 1, 2020 (Filed With SEC on September 14, 2020)

Series A-1 Warrant Agent Agreement, including form of Series A-1 Warrant, dated September 4, 2020 (Filed With SEC on September 14, 2020)

Series B-1 Warrant Agent Agreement, including form of Series B-1 Warrant, dated September 4, 2020 (Filed With SEC on September 14, 2020)

Form of Underwriting Agreement (Filed With SEC on August 28, 2020)

Form of Series A-1 Warrant Agent Agreement (including the terms of the Series A-1 Warrant) (Filed With SEC on August 28, 2020)

Form of Series B-1 Warrant Agent Agreement (including the terms of the Series B-1 Warrant) (Filed With SEC on August 28, 2020)

Form of Underwriters Warrant (Filed With SEC on August 28, 2020)

Amendment Agreement, dated August 19, 2020 (Filed With SEC on August 20, 2020)

Amendment Agreement, dated July 1, 2020, by and between the Company and Loma Linda University (Filed With SEC on August 13, 2020)

Form of Series A Warrant Agent Agreement (including the terms of the Series A Warrant) (Filed With SEC on June 25, 2020)

Form of Series B Warrant Agent Agreement (including the terms of the Series B Warrant) (Filed With SEC on June 25, 2020)

Form of Underwriting Agreement (Filed With SEC on June 24, 2020)

Form of Underwriters Unit Purchase Option (Filed With SEC on June 24, 2020)

Form of Underwriting Agreement (Filed With SEC on June 17, 2020)

Form of Warrant Agent Agreement (Filed With SEC on June 17, 2020)

Form of Underwriters Unit Purchase Agreement (Filed With SEC on June 17, 2020)

Form the Companys common stock certificate (Filed With SEC on May 14, 2020)

Form of Promissory Note issued to Sekris Biomedical, Inc (Filed With SEC on May 14, 2020)

Warrant, dated March 8, 2018, issued to Sekris Biomedical, Inc (Filed With SEC on May 14, 2020)

Form of Private Placement Subscription Agreement (Filed With SEC on May 14, 2020)

Patent Licensing Agreement, dated February 3, 2020 (Filed With SEC on May 14, 2020)

Patent and Technology License Agreement, dated March 15, 2018 between Loma Linda University and Aditx Therapeutics, Inc (Filed With SEC on May 14, 2020)

2017 Equity Incentive Plan and forms of award agreements thereunder (Filed With SEC on May 14, 2020)

Consulting Agreement, dated March 1, 2018 between Aditx Therapeutics, Inc. and Canyon Ridge Development LLC d/b/a Mission Critical Solutions International (Filed With SEC on May 14, 2020)

Form of July 2018 Securities Purchase Agreement (Filed With SEC on May 14, 2020)

Form of July 2018 Note (Filed With SEC on May 14, 2020)

Form of April 2018 Promissory Note (Filed With SEC on May 14, 2020)

Form of March 2019 Promissory Note (Filed With SEC on May 14, 2020)

Form of October 2019 Securities Purchase Agreement (Filed With SEC on May 14, 2020)

Form of October 2019 Note (Filed With SEC on May 14, 2020)

Form of January 2020 Note Purchase Agreement (Filed With SEC on May 14, 2020)

Form of January 2020 Private Placement Promissory Note (Filed With SEC on May 14, 2020)

Category

Industry

Companies

Contracts

ADiTx Therapeutics, Inc. Contracts & Agreements